Sagent Makes ‘Aggressive’ Moves In A ‘Challenging’ US Injectables Market

CEO Vishy Chebrol Talks To Generics Bulletin About Strategy Since Nichi Iko Divestment

 
• By Dave Wallace

With Sagent Pharmaceuticals operating in an increasingly competitive US injectables market, the company has recently been making moves to bolster its position in the wake of its separation last year from its former parent company, Japan’s Nichi Iko. Chief executive Vishy Chebrol talks to Generics Bulletin about the firm’s strategic goals.

Q&A wooden blocks
Vishy Chebrol, Sagent’s CEO, answers questions from Generics Bulletin • Source: Shutterstock

Sagent Pharmaceuticals is a major player in US injectables – but it is far from alone in the market, with competing players continuing in their efforts to carve out a space for themselves amid continuing supply challenges and shortages.

In the wake of Sagent’s recent transfer of ownership from former parent company, Japan’s Nichi Iko, to current owner Ellimist Singapore Pte – as part of a deal struck last year (Also see "Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America" - Generics Bulletin, 1 March, 2023

More from Strategy

More from Leadership